Proteomics Tools Report: Research & Clinical Markets, First Edition: 2025-2030

Download a sample of the report here.

This first edition report provides an overview of the proteomics tools market from 2025 to 2030. The market is defined by customer spend on internal tools and reagents that support proteomics research and clinical workstreams across academia, biopharma, CROs, and hospitals. The landscape is served by a diverse group of companies, with vendor choice depending on the specific application and technology. For routine diagnostics, established players with validated, low-plex platforms are preferred. In discovery and translational research, where higher-plex and novel technologies are required, more specialized providers are gaining significant traction.  

The proteomics tools market is poised for steady growth, driven by the direct relevance of the proteome to disease biology and the current pace of technological innovation. Emerging platforms are enabling deeper multiomic insights and are becoming essential for advancing precision medicine. However, the market faces headwinds, including the complexity of analyzing high-dimensional data, persistent funding pressures in academic research, and significant regulatory hurdles that slow the clinical adoption of novel research platforms. Balancing these factors, we estimate that the global proteomics tools market will grow from ~$32B in 2025 to approximately $39B by 2030, growing at ~4% annually.

This report is informed by a comprehensive primary and secondary research campaign, including N = 20 interviews and N = 50 surveys with stakeholders across the proteomics ecosystem. The market model is a top-down model based on the estimated revenues of key proteomics tool companies, segmented across key applications and customer types. We triangulated market growth using historical and forecasted organic growth from key players.

For each of the 25+ subsegments, we provide an analysis of company trends, investments, and overall market changes for 2025, 2028, and 2030. Additionally, we examine market drivers, moderators, and trends. The report also includes a high-level breakdown by customer (academia, biopharma, CRO, and clinical), product type (instrument vs. reagent) and analyte plex where appropriate.*

*Some of the companies listed in the report may be DeciBio Consulting clients and customers.

‍

Segmentations Covered in Market Analysis:

Technology/Tool Type

• Standard Immunoassays (ELISA, Western Blot)

• Conventional IHC/IF

• Mass Spectrometry

• Capillary Electrophoresis

• Protein Microarrays

• Spatial & Imaging Proteomics

• High Plex Affinity Assays

• Protein Sequencing

‍

Product Type

• Instruments

• Reagents

‍

Customer Type

• Academia

• Biopharma

• CRO

• Clinical

‍

Application/Use Case

• Basic / Functional Research & Discovery

• Preclinical Research

• Translational / Clinical Research

• Clinical Diagnostics

‍

Product Designation

• Research Use Only (RUO)

• In-Vitro Diagnostic (IVD)

‍

Plex Level

• 1-2 Plex

• 3-19 Plex

• 20-99 Plex

• 100+ Plex

‍

Geography

• United States

• Europe

• Asia Pacific (APAC)

• Rest of World (ROW)

‍